Palisade Bio, Inc. (PALI) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. The company's lead product candidate, PALI-2108, is being developed for inflammatory bowel disease (IBD), including fibrostenotic Crohn's disease and ulcerative colitis. The company is currently conducting a Phase 1 clinical trial in Canada and plans to submit an Investigational New Drug (IND) application to the U.S. FDA in 2025.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,230) | $(3,527) |
| Net Loss Per Share (Basic & Diluted) | $(0.47) | $(4.59) |
| Operating Expenses | $2,310 | $3,673 |
| Cash and Cash Equivalents (End of Period) | $7,230 | $11,276 |
| Net Cash Used in Operating Activities | $(2,333) | $(3,180) |
| Total Debt | $0 | $79 |
Note: The company has no product revenue. Total debt consists of insurance financing debt, which was fully paid off during Q1 2025.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately 37% (from $3.5M to $2.2M) compared to Q1 2024.
- Expense Reduction: Total operating expenses declined by 37% ($1.4M decrease).
- R&D Expenses: Decreased 57% ($1.3M drop) primarily due to the cessation of preclinical joint development costs with Giiant Pharma (which were $1.6M in Q1 2024) and a $0.7M reduction in expenses from funds received from Giiant. This was partially offset by a $1.1M increase in clinical trial costs for the Phase 1 study of PALI-2108.
- G&A Expenses: Decreased 7% ($0.1M drop) due to lower shareholder services, employee-related expenses, and insurance costs.
- Cash Position: Cash and cash equivalents decreased by approximately $2.6M during the quarter, driven by operating cash outflows and payments of equity issuance costs.
- Debt Repayment: The company fully repaid its insurance financing debt ($79k) during the quarter.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year following the issuance of the financial statements. Current cash resources ($7.2M) are projected to fund operations only through the fourth quarter of 2025.
- Capital Needs: The company will require additional financing beyond Q4 2025 to continue operations. Failure to secure capital could force the company to delay, scale back, or cease development activities.
- Clinical Progress: The Phase 1 clinical trial in Canada is ongoing. Topline data is anticipated in Q2 2025. If successful, a Phase 1b/2a study is planned for Q1 2026.
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to a lack of segregation of duties and formalized processes for journal entries and reconciliations. Remediation efforts are ongoing but not yet complete.
- Listing Compliance: The company received a notice from Nasdaq on April 30, 2025, regarding non-compliance with the $1.00 minimum bid price rule. The company is in a compliance period to regain standing.
Key Investor Verification Points
- Liquidity Runway: Verify the company's ability to raise capital before Q4 2025 to avoid operational disruption.
- Clinical Data Readout: Monitor the Q2 2025 announcement of Phase 1 topline data for PALI-2108, which is critical for future funding and development.
- Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 minimum bid price requirement to avoid delisting.
- Internal Control Remediation: Review future filings for confirmation that the material weakness in financial reporting has been remediated.
- Collaboration Terms: Review the amended Giiant Pharma agreement details regarding milestone payments and the payment cap reduction.